Thymosin Alpha-1
About
About Thymosin Alpha-1
Thymosin Alpha-1 (Tα1) is an endogenous thymic peptide with potent immunomodulatory and antiviral properties, approved in 37 countries for hepatitis B, hepatitis C, and as an immune adjuvant in cancer care. It is used in optimization medicine for immune restoration, chronic infection management, and as an adjunct in post-COVID recovery. Compounded Tα1 is available through US pharmacies. It has an exceptional safety profile with decades of clinical use.
Science
Mechanism of Action
Stimulates maturation and differentiation of T-cells, enhances NK cell activity, upregulates MHC class I expression on cells, and modulates Th1/Th2 cytokine balance — producing a broad immunostimulatory effect without autoimmune risk.
Dosing
Typical Protocol
1.6 mg subcutaneous injection 2x weekly for 6–12 months for immune restoration; shorter cycles used for acute protocols.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound is legal to prescribe and dispense through a licensed 503A or 503B compounding pharmacy with a valid prescription. It is not FDA-approved as a finished drug product, but compounding is explicitly permitted under federal law. Quality and sterility standards vary by pharmacy — look for PCAB-accredited compounders.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Thymosin Alpha-1 — with trust scores, legal credentials, and pricing transparency.